Nebuliser Solution : It is indicated for the treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD). It is also indicated, when used concomitantly with inhaled beta 2-agonists, for treatment of reversible airway obstruction as in acute and chronic ... Read more Nebuliser Solution : It is indicated for the treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD). It is also indicated, when used concomitantly with inhaled beta 2-agonists, for treatment of reversible airway obstruction as in acute and chronic asthma. Inhaler : As bronchodilator in the treatment of chronic reversible airway obstruction as in asthma and chronic obstructive pulmonary disease including chronic bronchitis and emphysema. Treatment of acute reversible airway obstruction.
Ipratropium Bromide is a quaternary ammonium compound with anticholinergic properties. It appears to inhibit vagal reflexes by antagonising the action of acetylcholine (the transmitter agent released from the vagus nerve). Anticholinergics prevent the increase in intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Adults: The usual dose is 1-2 puffs (20 gm/spray) three or four times daily. Single dose upto 80 gm (4 puffs) may be required to obtain maximum benefit during early treatment. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours. Children: 6-12 years: Usually 1-2 puffs two to three times daily. Below 6 years: The usual dose is 1 puff (20 gm) three times daily. In order to ensure that the inhaler is used correctly, the administration should be supervised by an adult. Elderly: No specific information on the use of the product in the elderly is available. Clinical trials have included patients over 65 years and no adverse reactions specific to this age group has been reported.
Nebuliser Solution: Common : Headache, Dizziness, Cough, Inhalation induced bronchospasm, Dryness of mouth, Vomiting. Uncommon : Urticaria, Tachycardia, Skin rash, Pruritus. Rare: Anaphylactic reaction, Eye pain, Mydriasis, Intraocular pressure increased, Palpitations, Atrial fibrillation, Nausea. Inhaler: Potentially life-threatening effects
Nebuliser Solution : Known hypersensitivity to atropine or its derivatives, or to any other component of the product. Inhaler : Known hypersensitivity to Ipratropium, Atropine or its derivative. Also contraindicated in patients with a history of hypersensitivity to soya lecithin or related food products such as soybean, lecithin and peanut.
Inhaler : G-Ipra has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, steroids and cromolyn sodium, commonly used in the treatment of chronic obstructive pulmonary disease, without adverse drug reactions. There are no studies fully evaluating the interaction effects of G-Ipra and these drugs with respect to effectiveness.
Nebuliser Solution : Use of the nebulizer solution should be subject to close medical supervision during initial dosing. Caution is advocated in the use of anticholinergic agents in patients with narrow-angle glaucoma, or with prostatic hyperplasia or bladder-outflow obstruction or cystic fibrosis. Immediate hypersensitivity reactions have been demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, oropharyngeal edema and anaphylaxis. There have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, narrow-angle glaucoma, eye pain) when aerosolized G-Ipra has come into contact with the eyes during nebulizer therapy. Patients must be instructed in the correct administration of the G-Ipra Nebulizer Solution. Care must be taken not to allow the solution or mist to enter the eyes. It is recommended that the nebulizer solution is administered via a mouthpiece. If a mouthpiece is not available and a nebulizer mask is used, it must fit properly. Inhaler : Patients should be advised that temporary blurring of vision precipitation or worsening of narrow-angle glaucoma or eye pain may result if the aerosol is sprayed into the eyes. If recommended dosage does not provide relief or symptoms become worse, patients should seek immediate medical attention. While taking G-Ipra inhalation aerosol, other inhaled drugs should not be used unless prescribed. G-Ipra inhalation aerosol is not indicated for the initial treatment of acute episodes of bronchospasm where rapid response is required. Drugs with faster onset may be preferable as initial therapy in this situation. Immediate hypersensitivity reactions may occur after administration of G-Ipra, as demonstrated by rare cases of urticaria, angio-oedema, rash, bronchospasm and oropharyngeal oedema.